Cargando…

An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

Diarrhea-predominant irritable bowel syndrome (IBS-D) is one of the most common chronic functional gastrointestinal diseases with limited treatments. Gut microbiota play an important role in chronic gastrointestinal diseases. In traditional Chinese medicine (TCM), Spleen–Yang deficiency (SYD) is one...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhen, Zhang, Xia, Lin, You, Huang, Jingwei, Zhou, Shasha, Yang, Xinyi, Wei, Wenjing, Lai, Xin, Zhang, Chaomei, Fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670173/ https://www.ncbi.nlm.nih.gov/pubmed/34916934 http://dx.doi.org/10.3389/fphar.2021.746923

Ejemplares similares

Rapid discovery of chemical constituents and absorbed components in rat serum after oral administration of Fuzi-Lizhong pill based on high-throughput HPLC-Q-TOF/MS analysis
por: Zhang, Zhen, et al.
Publicado: (2019)

Transcriptomic Analysis of Fuzi Lizhong Decoction for the Treatment of Stomach Ulcers
por: Xin, Yang, et al.
Publicado: (2020)

Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome
por: Mei, Lijun, et al.
Publicado: (2021)

Action Mechanism Underlying Improvement Effect of Fuzi Lizhong Decoction on Nonalcoholic Fatty Liver Disease: A Study Based on Network Pharmacology and Molecular Docking
por: Luo, Zheng, et al.
Publicado: (2022)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018)

Fuzi-Lizhong Decoction Alleviates Nonalcoholic Fatty Liver Disease by Blocking TLR4/MyD88/TRAF6 Signaling
por: Yang, Jiayao, et al.
Publicado: (2022)

Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Wu, Jing, et al.
Publicado: (2020)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
por: Carroll, Ian M, et al.
Publicado: (2010)

Network Pharmacology Identifies the Mechanisms of Action of Tongxie Anchang Decoction in the Treatment of Irritable Bowel Syndrome with Diarrhea Predominant
por: Tan, Xiang, et al.
Publicado: (2020)

Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome
por: Wang, Zhe, et al.
Publicado: (2019)

Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
por: Andrews, Christopher N, et al.
Publicado: (2019)

Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome
por: Wei, Wei, et al.
Publicado: (2020)

Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
por: Luo, Mei, et al.
Publicado: (2022)

Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
por: Li, Pingping, et al.
Publicado: (2020)

A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome
por: Zhao, Ling, et al.
Publicado: (2019)

Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome
por: Moser, Adrian Mathias, et al.
Publicado: (2018)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Effects and Mechanisms of Acupuncture on Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review
por: Zhang, Gezhi, et al.
Publicado: (2022)

Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial
por: Zheng, Hui, et al.
Publicado: (2016)

Altered Intestinal Microbiota with Increased Abundance of Prevotella Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome
por: Su, Tingting, et al.
Publicado: (2018)

Fecal Microbiota Transplantation Combined with a Low FODMAP Diet for the Treatment of Irritable Bowel Syndrome with Predominant Diarrhea
por: Huang, Hong-Li, et al.
Publicado: (2022)

Mucosal-Associated Microbiota Other Than Luminal Microbiota Has a Close Relationship With Diarrhea-Predominant Irritable Bowel Syndrome
por: Yang, Min, et al.
Publicado: (2020)

Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome
por: Aggarwal, Surbhi, et al.
Publicado: (2018)

Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
por: Arrouk, Rami, et al.
Publicado: (2018)

Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome
por: Katsumata, Ryo, et al.
Publicado: (2017)

Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome
por: Martoni, Christopher J, et al.
Publicado: (2023)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

No distinction in the gut microbiota between diarrhea predominant-irritable bowel syndrome and healthy subjects: matched case–control study in Thailand
por: Jandee, Sawangpong, et al.
Publicado: (2021)

Acupuncture for Adults with Diarrhea-Predominant Irritable Bowel Syndrome or Functional Diarrhea: A Systematic Review and Meta-Analysis
por: Guo, Jianbo, et al.
Publicado: (2020)

Epidemiology of Functional Diarrhea and Comparison with Diarrhea-Predominant Irritable Bowel Syndrome: A Population-Based Survey in China
por: Zhao, Yan-Fang, et al.
Publicado: (2012)

Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome
por: Zhan, Kai, et al.
Publicado: (2020)

Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
por: Colomier, Esther, et al.
Publicado: (2021)

Tong-Xie-Yao-Fang Regulates 5-HT Level in Diarrhea Predominant Irritable Bowel Syndrome Through Gut Microbiota Modulation
por: Li, Junchen, et al.
Publicado: (2018)

Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction
por: Zhang, Changrong, et al.
Publicado: (2020)

Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially
por: Jia, Qiong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gqgl6uor0dd318b0856sc4ui5n